Saccharomyces cerevisiae is an ascosporogenous yeast which has been successfully used in enzyme substitution therapy for congenital sucrase-isomaltase deficiency (2, 13) . In Western Europe, it is commercially available as a combination with activated charcoal (Laboratories UCB, Nanterre, France) for the treatment of functional disorders of the intestine such as colitis or diarrhea. Although the basis of this therapy was explained in a laboratory report on the nonspecific stimulation of phagocytosis by S. cerevisiae (16) , no controlled clinical trials of this treatment have been published. More-abundant data have been published on the effect of another yeast, Saccharomyces boulardii. The kinetics of intestinal elimination of this type of yeast have been studied in volunteers (4) , and administration of S. boulardii has been shown to inhibit the in vitro growth of various microorganisms (5) , increase resistance to colonization by Candida spp. (10) , and reduce Clostridium difficile-induced mortality in experimentally infected rodents (8, 19) . Although few authors have studied the antidiarrheal mechanism of action of S. boulardii (6, 20) , the results of several investigations, including a prospective placebo-controlled study, suggest that S. boulardii may reduce diarrhea in various clinical situations (7, 11, 14, 17, 18) .
In order to study whether similar results could be obtained with S. cerevisiae, we determined the kinetics of the elimination of S. cerevisiae after its oral absorption by healthy volunteers and the effect of this yeast on resistance to colonization in gnotobiotic mice.
Human volunteers. Six healthy, fully informed adult volunteers were included in the study. None Some of the mice were inoculated once intragastrically with 108 CFU of S. cerevisiae and then challenged by intragastric gavage 5 days later with 108 CFU of one of five potentially pathogenic bacterial strains: enterotoxigenic Escherichia coli H10407 (from J. P. Craig), Staphylococcus aureus IGR4310, Vibrio parahaemolyticus J525C, Vibrio cholerae 569B (from J. P. Craig), or C. difficile IGR786. The rest of the mice were first challenged with one of these strains and then continuously treated with S. cerevisiae from day 5 on. All mice were killed 10 days after the first inoculation. Each mouse's intestine from pylorus to rectum was then removed, and the jejunum, ileum, and cecum were separated, individually weighed, and ground with an UltraTurrax grinder (Bioblock, Illkirch, France). S. cerevisiae and the associated bacteria then were counted in each anatomical segment.
Bacterial counts. In monoassociated mice (i.e., mice treated with only one kind of bacterium), all bacterial strains were established at high populationl levels (Table 2 ). When S. cerevisiae was inioculated preventively, i.e., prinor to inoculation of bacterial strain, and counted 9 days later, less than i0' CFU/g of feces was found for all the bacterial strains inoculated except C.
difficile. By contrast, all the strains, including C. difficile, colonized the intestine of the pretreated mice at concentrations similar to those observed in the monoassociated mice. When S. cerevisiae was inoculated curatively, i.e., after the inoculation of bacterial strains, the counts for bacteria were unchanged but those for S. cerevisiae rose, ranging from 3.5 + 0.2 CFU/g of feces for E. coli H110407 to 6.0 ± 0.8 for V. cholerae 569B.
Administration of S. cerevisiae did not significantly modify the jejunal, ileal, or cecal counts of any of the strains inoculated into the monoassociated mice (data not shown).
Scanning electron microscopy studies (micrographs not shown) showed that high concentrations of yeast cells were present at the surface of the ileum of mice monoassociated with S. cerevisiae. However, this did not prevent V. parahaemolyticus J525C from also being present on the mucosa when this organism was inoculated after S. cerevisiae. In addition, when E. coli H10407 was administered before S. cerevisiae, almost no yeast cells were seen on the mucosa.
Our data show that volunteers who ingested S. cerevisiae excreted significant numbers of living yeast organisms throughout the 5 days of its administration. Fecal concentrations decreased rapidly after the end of the treatment, suggesting that no permanent implantation or multiplication of S. cerevisiae occurred. This is very similar to what had been observed with S. boulardii (4), a closely related yeast which has been shown to increase intestinal resistance to colonization markedly in experimental models (5, 8, 10, 16, 19) and to prevent or reduce diarrhea in various clinical situations (7, 14, 17, 18) .
To establish whether S. cerevisiae displays the same activity as S. boulardii, we studied the effects of S. cerevisiae on resistance to colonization by various enteropathogenic bacteria. For this purpose, we used gnotobiotic mice, as described previously (15) . We found that, contrary to what others observed with S. boulardii, none of the test strains was eliminated by the administration of S. cerevisiae, whether the latter was given before or after the test strain. Given that S. boulardii and S. cerevisiae may be closely NOTES 3051 related and that the test conditions were apparently not much different in the two studies, the differences observed may be more strain related than species related. Finally, when S. cerevisiae was administered first, its concentration decreased after administration of the test strains. Scanning electron microscopy pictures showed that when this occurred, very few yeast cells were associated with the intestinal mucosa.
Taken together, these results do not suggest that the alleged antidiarrheal effect of preparations containing S. cerevisiae is mediated by an increase in resistance to colonization by intestinal pathogens.
